Rethinking the significance of surgery for uterine cervical cancer.
chemotherapy
concurrent chemoradiotherapy
histological type
surgery
uterine cervical cancer
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
31
10
2021
accepted:
22
11
2021
pubmed:
16
12
2021
medline:
5
3
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Treatment strategies based on histological subtypes are unestablished. Rethinking the significance of surgery for uterine cervical cancer. Using the database of cervical cancer stages IB-IIB with extensive hysterectomy (Federation of Gynecology and Obstetrics [FIGO] 2008) established by the Japanese Gynecologic Oncology Group network, we conducted a clinicopathological study of cervical cancer cases reclassified according to the FIGO 2018 staging. In stage IB (FIGO 2018) cervical cancer patients, there was no significant difference in treatment outcome according to histological type, but in stages IIA, IIB, and IIIC1 (FIGO 2018), the treatment outcome of nonsquamous cell carcinoma was significantly worse than that of squamous cell carcinoma. Considering post-treatment health care, it is important to consider ovarian preservation in young patients with cervical cancer, up to stage IIA (FIGO 2018) for squamous cell carcinoma and stage IB1 (FIGO 2018) for nonsquamous cell carcinoma, after careful evaluation of clinicopathological factors before surgery. Locally advanced adenocarcinoma of the cervix is a rare and refractory cancer that has been shown to have low radiosensitivity, and its treatment outcome is still unsatisfactory. A new therapeutic strategy involving multidisciplinary treatment in combination with perioperative chemotherapy at a facility that can provide highly curative surgical treatment is desired. Minimally invasive surgery is being introduced for the treatment of early-stage cervical cancer. However, the number of eligible cases should be expanded in a phased manner, based on an objective evaluation of surgical outcomes at the facilities. Omics analysis may be useful to develop a new treatment for human papillomavirus nonrelated cervical cancer, represented by gastric mucinous carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment strategies based on histological subtypes are unestablished.
AIMS
OBJECTIVE
Rethinking the significance of surgery for uterine cervical cancer.
METHODS
METHODS
Using the database of cervical cancer stages IB-IIB with extensive hysterectomy (Federation of Gynecology and Obstetrics [FIGO] 2008) established by the Japanese Gynecologic Oncology Group network, we conducted a clinicopathological study of cervical cancer cases reclassified according to the FIGO 2018 staging. In stage IB (FIGO 2018) cervical cancer patients, there was no significant difference in treatment outcome according to histological type, but in stages IIA, IIB, and IIIC1 (FIGO 2018), the treatment outcome of nonsquamous cell carcinoma was significantly worse than that of squamous cell carcinoma. Considering post-treatment health care, it is important to consider ovarian preservation in young patients with cervical cancer, up to stage IIA (FIGO 2018) for squamous cell carcinoma and stage IB1 (FIGO 2018) for nonsquamous cell carcinoma, after careful evaluation of clinicopathological factors before surgery.
DISCUSSION
CONCLUSIONS
Locally advanced adenocarcinoma of the cervix is a rare and refractory cancer that has been shown to have low radiosensitivity, and its treatment outcome is still unsatisfactory. A new therapeutic strategy involving multidisciplinary treatment in combination with perioperative chemotherapy at a facility that can provide highly curative surgical treatment is desired.
CONCLUSION
CONCLUSIONS
Minimally invasive surgery is being introduced for the treatment of early-stage cervical cancer. However, the number of eligible cases should be expanded in a phased manner, based on an objective evaluation of surgical outcomes at the facilities. Omics analysis may be useful to develop a new treatment for human papillomavirus nonrelated cervical cancer, represented by gastric mucinous carcinoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
576-586Subventions
Organisme : JSPS KAKENHI
ID : JP17K11265
Informations de copyright
© 2021 Japan Society of Obstetrics and Gynecology.
Références
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191-203.
Yaegashi N. (2020) gynecologic cancer committee report in 2018. Acta Obstet Gynaecol Jpn. 2021;72:800-56.
Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer. 2008;113:2855-64.
National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Cervical Cancer NCCN Evidence Blocks™ Version 1.2021-August 14, 2020. https://www.nccn.org/professionals/physician_gls/pdf/cervical_blocks.pdf, Accessed: Oct 25, 2021.
Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M, Tashiro H, et al. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2019;24:1-19.
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143:22-36.
Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol. 2000;26:464-7.
Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 2006;95:S43-103.
Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. 2012;125:287-91.
Tsuji K, Shimada M, Takahashi F, Tokunaga H, Deura I, Yamaguchi S, et al. Clinico-pathological characteristics of patients with stage IB1-IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan. Int J Clin Oncol. 2021;26:1541-52.
Matsuo K, Shimada M, Yamaguchi S, Kanao H, Nakanishi T, Saito T, et al. Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer. Int J Cancer. 2018;142:1022-32.
Matuo K, Shimada M, Mikami M. Ovarian conservation for young women with clinical stage IB-IIB cervical cancer in Japan. J Gynecol Oncol. 2017;28:360.
Matsuo K, Shimada M, Yamaguchi S, Matoda M, Nakanishi T, Kikkawa F, et al. Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol. 2019;133:1086-98.
Matsuo K, Shimada M, Yamaguchi S, Kigawa J, Tokunaga H, Tabata T, et al. Neoadjuvant chemotherapy with taxane and platinum followed by radical hysterectomy for stage IB2-IIB cervical cancer: impact of histology type on survival. J Clin Med. 2019;8:156.
Matsuo K, Shimada M, Yokota H, Satoh T, Katabuchi H, Kodama S, et al. Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. Oncotarget. 2017;8:106866-75.
Matsuo K, Shimada M, Aoki Y, Sakamoto M, Takeshima N, Fujiwara H, et al. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: systemic chemotherapy versus pelvic irradiation. Int J Cancer. 2017;141:1042-51.
Matsuo K, Shimada M, Nakamura N, et al. Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer. Eur J Surg Oncol. 2019;45:1417-24.
Matsuzaki S, Klar M, Mikami M, Shimada M, Grubbs BH, Fujiwara K, et al. Management of stage IIB cervical cancer: an overview of the current evidence. Curr Oncol Rep. 2020;22:28.
Matsuo K, Shimada M, Saito T, et al. Risk stratification models for Para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer. J Gynecol Oncol. 2018;29:e11.
Matsuo K, Shimada M, Matsuzaki S, Machida H, Nagase Y, Saito T, et al. Significance of malignant peritoneal cytology on the survival of women with early-stage cervical cancer: a Japanese gynecologic oncology group study. J Clin Med. 2019;8:1822.
Matsuo K, Shimada M, Matsuzaki S, Enomoto T, Mikami M. Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: a treatment implication during the coronavirus pandemic. Eur J Cancer. 2021;148:117-20.
Shimada M, Tokunaga H, Kigawa J, Yaegashi N. Impact of histological risk factors on the treatment of stage IB-IIB uterine cervical cancer. Tohoku J Exp Med. 2020;252:339-51.
Machida H, Matsuo K, Matsuzaki S, Yamagami W, Ebina Y, Kobayashi Y, et al. Proposal of two-tier system in grouping adenocarcinoma of the uterine cervix. Cancer. 2020;12:1251.
Shimada M, Kigawa J, Nishimura R, Yamaguchi S, Kuzuya K, Nakanishi T, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol. 2006;101:234-7.
Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 2017;28:e34.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, et al. Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (bulky tumors) in Japan: a survey of the Japanese gynecologic oncology group. Int J Gynecol Cancer. 2014;24:1333-40.
Lee JY, Kim YT, Kim S, Lee B, Lim MC, Kim JW, et al. Prognosis of cervical cancer in the era of concurrent chemoradiation from national database in Korea: a comparison between squamous cell carcinoma and adenocarcinoma. PLoS One. 2015;10:e0144887.
Niibe Y, Kenjo M, Onishi H, Ogawa Y, Kazumoto T, Ogino I, et al. High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007). Jpn J Clin Oncol. 2010;40:795-9.
Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80:429-36.
Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K, et al. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol. 2017;28:e19.
Miyahara S, Tsuji K, Shimada M, et al. The impact of histological subtype on survival outcome of patients with stage IIB-IVA cervical cancer who received definitive radiotherapy. Tohoku J Exp Med. 2021; (in press).
Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan clinical oncology group trial (JCOG 0102). Br J Cancer. 2013;108:1957-63.
Yamaguchi S, Nishimura R, Yaegashi N, et al. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese gynecologic oncology group study (JGOG 1065). Oncol Rep. 2012;28:487-93.
Uegaki K, Shimada M, Sato S, Deura I, Naniwa J, Sato S, et al. Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. Int J Clin Oncol. 2014;19:348-53.
Shimada M, Nagao S, Fujiwara K, Takeshima N, Takizawa K, Shoji T, et al. Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. Int J Clin Oncol. 2016;21:1128-35.
Tanioka M, Yamaguchi S, Shimada M, et al. Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. Med Oncol. 2017;34:134.
Nagao S, Yamamoto K, Oishi T, Yamaguchi S, Takehara K, Shimada M, et al. Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer. Int J Clin Oncol. 2021;26:207-15.
Kojima A, Shimada M, Mikami Y, Nagao S, Takeshima N, Sugiyama T, et al. Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the Sankai gynecology study group. Int J Gynecol Cancer. 2018;28:99-106.
Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri (Chopra) S, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36:1548-55.
Kenter G, Greggi S, Vergote I, Katsaros D, Kobierski J, Massuger L, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer. J Clin Oncol. 2019;37(15_suppl):5503.
Hosaka M, Watari H, Takeda M, Moriwaki M, Hara Y, Todo Y, et al. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J Obstet Gynaecol Res. 2008;34:552-6.
Deura I, Shimada M, Hirashita K, Sugimura M, Sato S, Sato S, et al. Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy. Int J Clin Oncol. 2015;20:556-60.
Shimada M, Nishimura R, Nogawa T, et al. Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU intergroup surveillance. Mol Clin Oncol. 2013;1:780-4.
Ikeda Y, Furusawa A, Kitagawa R, Tokinaga A, Ito F, Ukita M, et al. Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan. J Gynecol Oncol. 2016;27:e29.
Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, et al. Postoperative chemotherapy for node-positive cervical cancer: results of a multicenter phase II trial (JGOG1067). Gynecol Oncol. 2018;149:513-9.
Takekuma M, Shimokawa M, Nishio S, Omi H, Tabata T, Takei Y, et al. Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis. Cancer Sci. 2018;109:1602-8.
Sato S, Shimada M, Ohta T, Kojimahara T, Tokunaga H, Takano T, et al. Feasibility study of adjuvant chemotherapy using taxane plus carboplatin for high-risk patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy. Int J Gynecol Cancer. 2016;26:561-7.
Ikeda M, Shida M, Shigeta S, Nagase S, Takahashi F, Yamagami W, et al. The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee. J Gynecol Oncol. 2021;32:e44.
Furusawa A, Takekuma M, Mori M, et al. A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese gynecologic oncology group study (JGOG1082). Int J Gynecol Cancer. 2021;31:623-6.
Sakuragi N, Kato T, Shimada C, Kaneuchi M, Todo Y, Mitamura T, et al. Oncological outcomes after Okabayashi-Kobayashi radical hysterectomy for early and locally advanced cervical cancer. JAMA Netw Open. 2020;3:e204307.
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895-904.
Melamed A, Margul DJ, Chen L, Keating NL, del Carmen MG, Yang J, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018;379:1905-14.
Nasioudis D, Albright BB, Ko EM, Haggerty AF, Giuntoli RL II, Kim SH, et al. Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size ≤ 2cm: a systematic review and meta-analysis. Int J Gynecol Cancer. 2021;3:983-90.
Kobayashi E, Kanao H, Takekuma M, Nishio S, Kojima-Chiba A, Tozawa A, et al. A retrospective assessment of the safety and efficacy of laparoscopic radical hysterectomy in Japan during the early years following its introduction: a Japanese gynecologic oncology group study (JGOG1081S). Int J Clin Oncol. 2021;26:417-28.
Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Surg Pathol. 2010;177:2169-75.
Mikami Y. Gastric-type mucinous carcinoma of the cervix and its precursors-historical overview. Histopathology. 2020;76:102-11.
Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix -an aggressive tumor with a poor prognosis: a multi-institutional study. Gynecol Oncol. 2019;153:13-9.
Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007;31:664-72.
Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, van Hummelen P, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013;119:3776-83.
Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506:371-5.
Matsuo K, Machida H, Mandelbaum R, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019;152:87-93.
Wright JD, Matsuo K, Haung Y, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol. 2019;134:49-57.
McComas KN, Torgeson AM, Ager BJ, et al. The variable impact of positive lymph nodes in cervical cancer: implications of the new FIGO staging system. Gynecol Oncol. 2020;156:85-92.